Learn the steps in de-risking drug and device integration in this webinar sponsored by West Pharmaceutical Services.

MDDI Staff

February 27, 2023

1 Min Read
IMG_2023-2-27-084943.jpg
Image credit: Olena Poliakevych/ iStock via Getty Images

Combination products are undergoing tremendous growth, driven by the rise in chronic disease indications, demand for self-administered therapies, minimally invasive procedures, and technology advancements. However when transitioning from a vial system to a needle-based combination product, there are many challenges in areas of government regulations, supply chain complexity, and patient outcomes. This webinar addresses these challenges, proper life cycle management, and the transition to a combination product.

  • The steps to de-risking drug and device integration

  • Strategies to de-risk the product development process and user testing

  • A greater understanding of data needed to support device reliability and robustness

Jen Riter, Senior Director, Business and Technical Operations for Services & Solutions
West Pharmaceutical Services, and Daniel Bantz Manager, Scientific Communications, Self-Injection Systems
West Pharmaceutical Services, will be the speakers. 

Get registered here for this transformative webinar. 

Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like